Article

Physical Activity Associated with Reduction in Cancer Mortality Risk

Exercise following diagnosis may offer significant protection among cancer survivors.

Exercise following diagnosis may offer significant protection among cancer survivors.

A recent analysis of the World Health Organization’s (WHO) recommendations for physical activity in order to reduce the risk of mortality from chronic diseases yielded a positive association between increased physical activity and decreased mortality for patients with cancer.

Scientists searched MEDLINE and EMBASE until May 2014 for cohort studies evaluating physical activity and cancer mortality in the general population and cancer survivors.

Combined HRs were estimated using fixed-effect or random-effect meta-analysis of binary analysis.

By using 2-stage random-effects dose-response meta-analysis, associated HRs with defined increments and recommended levels of recreational physical activity were determined.

Of the multitude of studies available, 71 were analyzed.

The results showed that those individuals who participated in the most physical activity had an HR of 0.83 and 0.78 for cancer mortality in the general population and among cancer survivors, respectively.

In the general population, moderate-intensity activity for 2.5 h/week was associated with a 13% reduction in cancer mortality.

Cancer survivors who completed 15 metabolic equivalents of task (MET)-h/week of physical activity decreased their risk of cancer mortality by 27%.

Greater protection against this risk was associated with cancer survivors who undertook physical activity post diagnosis as opposed to pre-diagnosis.

This meta-analysis supports the recommendations by the WHO that physical activity will lead to a reduction of cancer mortality risk both in the general population and in cancer survivors.

“We infer that physical activity after a cancer diagnosis may result in significant protection among cancer survivors,” the study authors concluded.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards